Literature DB >> 29300711

Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?

John P Neoptolemos1, Christopher M Halloran, Paula Ghaneh, Jorg Kleeff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29300711     DOI： 10.1097/SLA.0000000000002026

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  3 in total

1.  Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience.

Authors:  Yung-Yeh Su; Yu-Lin Ting; Chih-Jung Wang; Ying-Jui Chao; Ting-Kai Liao; Ping-Jui Su; Nai-Jung Chiang; I-Chuang Liao; Yu-Ting Yu; Yi-Sheng Liu; Hong-Ming Tsai; Yi-Jie Li; Chien-Jui Huang; I-Ting Liu; Hui-Jen Tsai; Chia-Jui Yen; Yan-Shen Shan; Li-Tzong Chen
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review.

Authors:  Qiaofei Liu; Ronghua Zhang; Christoph W Michalski; Bing Liu; Quan Liao; Jorg Kleeff
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

3.  A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Li-Xia Wu; Xiao-Yong Wang; Ke-Qun Xu; Yu-Li Lin; Wen-Yu Zhu; Long Han; Yue-Ting Shao; Han-Yu Zhou; Hua Jiang; Jun-Jie Hang; Xu-Guang Yang
Journal:  J Cancer       Date:  2019-10-22       Impact factor: 4.207
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.